Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...

Hims & Hers Health Inc.’s shares jumped Tuesday after it said it was broadening its weight-loss offerings, adding access to ...

The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.

Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical ...

Eli Lilly's foray into telehealth shows the emerging importance virtual care platforms are playing in the rising popularity ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment ...

The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

It was previously corrected to change the brokerage's name to Leerink Partners, not Jefferies, in paragraph 4) Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's ...

Shares of Hims & Hers closed 5.1% higher after the company said it will expand its weight-loss offerings with branded versions of Lilly's tirzepatide — the active ingredient in weight-loss drug ...